相关实验视频

Updated: May 3, 2026

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

[光动力疗法后患有恶性质瘤的长期存活患者]

A Yu Rynda¹, V E Olyushin¹, D M Rostovtsev¹

¹Polenov Russian Neurosurgical Institute - a branch Almazov of the National Medical Research Center, St. Petersburg, Russia.

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

|July 29, 2024

概括

长期质母细胞瘤存活率受到患者年龄,手术程度和化疗的影响. 关键的分子因素包括MGMT促进物甲基化和IDH突变,显著影响患者的预后.

科学领域:

神经瘤学神经瘤学
癌症治疗治疗癌症治疗
分子诊断学分子诊断学

背景情况:

质母细胞瘤是一种具有有限治疗选择的侵袭性脑瘤.
光动力疗法 (PDT) 是作为复杂质母细胞瘤治疗的一部分被探索的.
确定影响长期生存的因素对于患者管理至关重要.

研究的目的:

分析使用光动力学疗法治疗的长寿质母细胞瘤患者.
评估各种临床,组织学和分子因素对患者预期寿命的影响.

主要方法:

对接受包括PDT在内的复杂治疗的63名质母细胞瘤患者的回顾性分析.
评估临床 (年龄,卡诺夫斯基指数,瘤特征),组织学,免疫组织化学 (Ki-67,p53) 和分子 (VEGF,MGMT,IDH,CD34) 的因素.
对治疗参数 (辐射,化疗) 与生存结果的相关性分析.

主要成果:

预期寿命与MGMT状态,IDH状态,化疗疗程,患者年龄和手术干预严重程度有直接相关性.
诊断时的年龄,手术切除程度和化疗量是生存的重要预测因素.
MGMT促进物甲基化和IDH突变成为长期生存的最关键的分子决定因素.

结论:

年龄,手术程度和化疗等临床因素对于预测质母细胞瘤患者的存活率非常有价值.
分子标记物,特别是MGMT促进物甲基化和IDH突变,对于确定质母细胞瘤患者的长期结果至关重要.
这些发现可以为质母细胞瘤的个性化治疗策略提供信息.

关键词:

长期存活率长期存活率恶性质质瘤是一种恶性质瘤.神经瘤学神经瘤学光动力学疗法是一种光动力学疗法.

更多相关视频

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...